Zdrowie i gospodarka · 22/06/2018

FDA Classifies Next Generation Sequencing Based Tumor Profiling Test as Class II Device with Special Controls

The FDA has classified the next generation sequencing based tumor profiling test as a Class II device with special controls, aiming to ensure safety and effectiveness while reducing regulatory burdens and enhancing patient access to innovative devices.